Stocks · News reference
The submission advances Natera’s growing presence in Japan, where Signatera received PMDA approval in colorectal cancer in June, becoming the country’s first PMDA-approved molecular residual disease (MRD) test.The MIBC
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Angiex is conducting a Phase I clinical trial of AGX101, an investigational TM4SF1-directed ND-ADC. AGX101 is designed to bind TM4SF1 and deliver a cytotoxic payload to TM4SF1-expressing tumor cells and tumor-associated
Read original at benzingaCitigroup analyst Brendan Digan maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $315 to $365.
Read original at benzingaPiper Sandler analyst David Westenberg maintains Natera (NASDAQ:NTRA) with a Overweight and raises the price target from $249 to $363.5.
Read original at benzingaStephens & Co. analyst Mason Carrico maintains Natera (NASDAQ:NTRA) with a Overweight and raises the price target from $305 to $350.
Read original at benzinga